Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892385 · ClinicalTrials.gov registry record · Phase 1
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00892385: Completed Phase 1 study, sponsored by Case Comprehensive Cancer Center.
NCT00892385 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00892385, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as methoxyamine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of methoxyamine when given together with temozolomide in treating patients with advanced solid tumors.
Primary Outcome
A total of 38 patients were analyzed to determine the maximum tolerated dose of methoxyamine in this study and this was determined in the non-CNS arm. An initial 6 patients received treatment with continuous dosing of methoxyamine and based on an assessment of pharmacokinetics, in this group, the study was revised to administer methoxyamine as a bolus dose. Thirty-eight patients received this type of dosing.
Interventions
- DRUG Temozolomide
- DRUG Methoxyamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2007-08-16 |
| Est. Completion | 2017-03-08 |
| Phase | Phase 1 |
What the finished NCT00892385 record still lists
NCT00892385 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00892385 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00892385 about?
NCT00892385 is a clinical study titled "Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as methoxyamine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving methoxyamine together with temozolomide may kill more tumor cells. PURPOSE: This phase I tria...
What is the current status of trial NCT00892385?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2007-08-16. Estimated completion is 2017-03-08.
What interventions are being tested in trial NCT00892385?
The interventions under investigation include: Temozolomide (DRUG), Methoxyamine (DRUG).
Who is sponsoring clinical trial NCT00892385?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00892385's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI